Developer docs
API playgroundTry for free, no card

Search company profiles

Cellectricon

Full company profile

uuid000evvr

Namestring
Cellectricon
Company typeenum
Private
Founded yearint
2001
Descriptiontext

Cellectricon is a Swedish life sciences services company founded in 2001 and headquartered in Mölndal, Sweden. The company provides advanced cell-based screening services that support pharmaceutical drug discovery, with a specialization in neuroscience and neurotoxicity assessment. Its core offering is the Neuroscience Discovery Platform, which combines validated in vitro models with three advanced assay technologies: optical electrophysiology assays that read neural activity through optical methods, high-content imaging for comprehensive cellular and neural response analysis, and microfluidic lab-on-a-chip systems that enable controlled environments for acute and chronic neurotoxicity endpoint evaluation. In November 2025, Cellectricon launched dedicated Neurotoxicity Testing Services as an extension of this platform to address early-stage safety assessment of drug candidates.

The company serves pharmaceutical and biotechnology drug developers through a B2B professional services model, with a current strategic focus on developers of oligonucleotide-based therapeutics, a growing drug class whose unique mechanisms require specialized neurotoxicity evaluation. Revenue is generated through individually negotiated service contracts for custom in vitro testing engagements, with pricing quoted on a per-engagement basis rather than through published rate cards. The go-to-market is direct enterprise sales targeting pharma and biotech decision-makers, consistent with the specialized, high-touch nature of contracted laboratory services.

Cellectricon operates with a small team of 11-50 employees and has historically been lightly funded, with its last disclosed institutional round closing in 2004 (approximately $7M led by Investor Growth Capital and Karolinska, on top of two prior rounds totaling roughly $6.8M). Leadership is held by CEO Mattias Karlsson and COO Johan Pihl. The company has no disclosed app product, API, public-company listing, or active M&A activity based on the available data.

Short descriptiontext

Cellectricon is a Swedish life sciences services company that provides cell-based screening and neurotoxicity testing to pharmaceutical and biotech drug developers, using validated in vitro models with optical electrophysiology, high-content imaging, and microfluidic assay systems.

Operating statusenum
Operating
Ownership categoryenum
Headcount rangeband
11–50
akta.pro rankint
HeadquartersMölndal, Sweden
HQ citystring
Mölndal
HQ countrystring
Sweden
HQ regionstring
Europe
Markets served

Serves global market

Keyword5 values
in vitro neurotoxicity testing, cell-based screening services, neuroscience drug discovery, preclinical safety assessment, oligonucleotide therapeutics testing
Industry3 codes
PRIMARYHLAGAFAJ
In Vitro Toxicology (Cell-based/Organ-on-chip)
Healthcare & Life Sciences/Life Science Tools & Services (CRO/CDMO/Lab Services)/Preclinical Services (Toxicology/Pharmacology/DMPK)
SECONDARYHLAIALAC
Preclinical Development (Pharmacology, PK/PD, ADME, Toxicology)
Healthcare & Life Sciences/Pharmaceuticals/Pharmaceutical Research and Development
SECONDARYHLAGAFAB
Safety Pharmacology (Cardio/CNS/Respiratory)
Healthcare & Life Sciences/Life Science Tools & Services (CRO/CDMO/Lab Services)/Preclinical Services (Toxicology/Pharmacology/DMPK)
NAICS code2 codes
  • Research and Development in Biotechnology (except Nanobiotechnology)541714
  • Scientific Research and Development Services5417
SIC code2 codes
  • Services-Testing Laboratories8734
  • Services-Commercial Physical & Biological Research8731
Product category
Preclinical Contract Research Organization (CRO) Services
Social media profiles2 records
GTM motion1 record

Each record includes

Type, Description, Source

Revenue model1 record
1Neurotoxicity Testing Services
TypeProfessional Services
Description

Contracted testing services provided to pharmaceutical and biotech companies for early-stage safety assessment of drug candidates. Revenue is generated through service contracts for in vitro neurotoxicity testing using the company's validated models and advanced assay technologies.

technologynetworks.com
Distribution channels1 record

Each record includes

Title, Type, Scope, Target buyer, Description, Source

Cost components5 values
Personnel, Operations, Technology or R&D, Infrastructure, Marketing or Sales
GTM typeB2B
B2B
Offering typeServices
Services
Core offering1 text field

Cellectricon provides advanced cell-based in vitro neurotoxicity testing services for pharmaceutical and biotech drug developers. Using validated human-relevant neural models combined with optical electrophysiology, high-content imaging, and microfluidic assay systems, the company evaluates acute and chronic neurotoxicity endpoints in drug candidates during preclinical development. The service is particularly positioned for developers of oligonucleotide-based therapeutics who require specialized early-stage safety assessment.

Differentiator
Functional benefit
Problem solved
Product overview1 text field

Cellectricon offers a neuroscience discovery platform as its core offering, augmented by specialized testing services. The platform provides drug discovery and safety assessment services, with the Neurotoxicity Testing Services representing a new module that expands the platform's early safety assessment capabilities. The services utilize in vitro models with advanced assay technologies including optical electrophysiology, high-content imaging, and microfluidic systems to evaluate neurotoxicity endpoints.

Product and service2 records
1Neurotoxicity Testing Services
CategoryPreclinical Safety Testing Services
Description

In vitro neurotoxicity testing services that leverage validated models with advanced assays including optical electrophysiology, high-content imaging, and microfluidic systems to evaluate acute and chronic neurotoxicity endpoints of drug candidates. Aimed at pharmaceutical and biotech developers, particularly those working on oligonucleotide-based therapeutics.

2Neuroscience Discovery Platform
CategoryNeuroscience Drug Discovery Services
Description

Cellectricon's core platform providing neuroscience research and cell-based screening services for drug discovery, now expanded to include neurotoxicity testing capabilities for early safety assessment of drug candidates.

Recent move5 records

Each record includes

Date, Type, Title, Description, Source

Expansion highlight4 records

Each record includes

Type, Description

Peers10 records
TypeDirect peer
Description

Preclinical services provider offering in vitro pharmacology, DMPK, and safety assays. Comparable as a contract research services firm serving pharma and biotech discovery and safety workflows.

TypeBroad incumbent
Description

Global preclinical CRO offering extensive safety assessment, neurotoxicology, and in vitro services. Directly comparable as a scaled incumbent competing for the same outsourced neurotoxicity testing budgets.

TypeDirect peer
Description

Specialized CRO focused on electrophysiology and in vitro neuroscience assays for drug discovery. Directly comparable as a niche electrophysiology services provider competing in the same neurotoxicology testing space.

TypeDirect peer
Description

Preclinical CRO providing toxicology, safety pharmacology, and research models. Comparable as a direct competitor in contract preclinical safety and neurotoxicity testing services.

TypeBroad incumbent
Description

Life sciences tools and services company offering reagents, assays, and contract services including neuroscience applications. Comparable as an established player providing both enabling tools and adjacent services to neuroscience drug discovery.

TypeBroad incumbent
Description

Large global CRO/CDMO offering preclinical toxicology and safety assessment services. Comparable as a scaled alternative for pharmaceutical customers seeking outsourced neurotoxicology testing.

TypeBroad incumbent
Description

Part of Eurofins Scientific, offering drug discovery, in vitro pharmacology, and safety screening services. Comparable as a broad life-sciences services provider with overlapping in vitro neuroscience and toxicology capabilities.

TypeBroad incumbent
Description

Global CRO offering in vitro and in vivo preclinical services including safety assessment. Comparable as a broad preclinical services competitor for outsourced neurotoxicology testing.

TypeDirect peer
Description

Specialist ion channel and neuroscience CRO offering electrophysiology and in vitro safety assays. Closely comparable as a niche preclinical services provider with overlapping electrophysiology-based neurotoxicology capabilities.

TypeDirect peer
Description

Provides preclinical in vitro ADME, toxicology, and safety pharmacology services through Cyprotex. Closely comparable as a specialized in vitro toxicology services provider supporting drug discovery safety assessment.

Market position
Strengths4 records

Each record includes

Headline, Details, Source

Weaknesses4 records

Each record includes

Headline, Details, Source

Competitive moat3 records

Each record includes

Type, Details

Key risks5 records

Each record includes

Headline, Details, Source

Key highlights5 records

Each record includes

Headline, Details, Source

Customer concentration

Classification, Details

Segment1 record

Each record includes

Title, Type, Primary, Description, Pain point addressed, Use case, Source

Ideal customer profile1 record

Each record includes

Profile, Firmographic size, Sales motion, Sales cycle length, Buying structure, Purchase trigger, Buyer persona, Geography, Industry vertical, Primary use case, Description, Pain points, Evidence proof points, Target buyer

Technology focused
Yes
API detail
Has APIbool
No

Docs URL, Description

AI maturity
App detail

Has app

Feature3 records

Each record includes

Title, Differentiator, Description, Source

Core technology
Revenue estimate
Valuation estimate
Number of profiles
Profiles2 records

Each record includes

Name, Designation, Designation category, Overview, Profile commentary, Source

No data
No data
Funding overview

Funding stage, Last funding date, Total funding USD

Funding rounds3 records

Each record includes

Round, Amount USD, Date, Pre money valuation, Total investors, Investors, News

Investors2 records

Each record includes

Name, Type, Date of entry, Rounds participated, Website

Funding detail is available on the Subscription and Enterprise plan.Contact sales →

M&A

Each record includes

Name, Acquisition type, Announced date, Completed date, Status, Website, News

Investment

Each record includes

Name, Round, Announced date, Lead investor, Website, News

M&A and investment is available on the Subscription and Enterprise plan.Contact sales →

Cellectricon

Preclinical Contract Research Organization (CRO) Servicescellectricon.com

Cellectricon is a Swedish life sciences services company that provides cell-based screening and neurotoxicity testing to pharmaceutical and biotech drug developers, using validated in vitro models with optical electrophysiology, high-content imaging, and microfluidic assay systems.

What Cellectricon does

Cellectricon is a Swedish life sciences services company founded in 2001 and headquartered in Mölndal, Sweden. The company provides advanced cell-based screening services that support pharmaceutical drug discovery, with a specialization in neuroscience and neurotoxicity assessment. Its core offering is the Neuroscience Discovery Platform, which combines validated in vitro models with three advanced assay technologies: optical electrophysiology assays that read neural activity through optical methods, high-content imaging for comprehensive cellular and neural response analysis, and microfluidic lab-on-a-chip systems that enable controlled environments for acute and chronic neurotoxicity endpoint evaluation. In November 2025, Cellectricon launched dedicated Neurotoxicity Testing Services as an extension of this platform to address early-stage safety assessment of drug candidates.

The company serves pharmaceutical and biotechnology drug developers through a B2B professional services model, with a current strategic focus on developers of oligonucleotide-based therapeutics, a growing drug class whose unique mechanisms require specialized neurotoxicity evaluation. Revenue is generated through individually negotiated service contracts for custom in vitro testing engagements, with pricing quoted on a per-engagement basis rather than through published rate cards. The go-to-market is direct enterprise sales targeting pharma and biotech decision-makers, consistent with the specialized, high-touch nature of contracted laboratory services.

Cellectricon operates with a small team of 11-50 employees and has historically been lightly funded, with its last disclosed institutional round closing in 2004 (approximately $7M led by Investor Growth Capital and Karolinska, on top of two prior rounds totaling roughly $6.8M). Leadership is held by CEO Mattias Karlsson and COO Johan Pihl. The company has no disclosed app product, API, public-company listing, or active M&A activity based on the available data.

Cellectricon firmographics

Firmographics
Name
Cellectricon
Website
https://cellectricon.com
Company type
Private
Founded year
2001
Operating status
Operating
Headcount range
11–50 employees
Short description
Cellectricon is a Swedish life sciences services company that provides cell-based screening and neurotoxicity testing to pharmaceutical and biotech drug developers, using validated in vitro models with optical electrophysiology, high-content imaging, and microfluidic assay systems.
Ownership category
akta.pro rank

Cellectricon industry classification

Industry
Product category
Preclinical Contract Research Organization (CRO) Services
NAICS
Research and Development in Biotechnology (except Nanobiotechnology) (541714), Scientific Research and Development Services (5417)
SIC
Services-Testing Laboratories (8734), Services-Commercial Physical & Biological Research (8731)
akta.pro industry
PRIMARYHLAGAFAJ
In Vitro Toxicology (Cell-based/Organ-on-chip)
Healthcare & Life Sciences/Life Science Tools & Services (CRO/CDMO/Lab Services)/Preclinical Services (Toxicology/Pharmacology/DMPK)
SECONDARYHLAIALAC
Preclinical Development (Pharmacology, PK/PD, ADME, Toxicology)
Healthcare & Life Sciences/Pharmaceuticals/Pharmaceutical Research and Development
SECONDARYHLAGAFAB
Safety Pharmacology (Cardio/CNS/Respiratory)
Healthcare & Life Sciences/Life Science Tools & Services (CRO/CDMO/Lab Services)/Preclinical Services (Toxicology/Pharmacology/DMPK)

Keywords

  • In vitro neurotoxicity testing
  • Cell-based screening services
  • Neuroscience drug discovery
  • Preclinical safety assessment
  • Oligonucleotide therapeutics testing

Where Cellectricon is headquartered

Location

Headquarters

HQ city
Mölndal
HQ country
Sweden
HQ region
Europe

Markets served

Cellectricon business model

Business model
GTM type
B2B
Offering type
Services
Cost components
Personnel, Operations, Technology or R&D, Infrastructure, Marketing or Sales

Revenue model

  1. Neurotoxicity Testing Services: Contracted testing services provided to pharmaceutical and biotech companies for early-stage safety assessment of drug candidates. Revenue is generated through service contracts for in vitro neurotoxicity testing using the company's validated models and advanced assay technologies.

Go-to-market motion1 record

Distribution channels1 record

Cellectricon product offering

Product offering

Core offering

Cellectricon provides advanced cell-based in vitro neurotoxicity testing services for pharmaceutical and biotech drug developers. Using validated human-relevant neural models combined with optical electrophysiology, high-content imaging, and microfluidic assay systems, the company evaluates acute and chronic neurotoxicity endpoints in drug candidates during preclinical development. The service is particularly positioned for developers of oligonucleotide-based therapeutics who require specialized early-stage safety assessment.

Product overview

Cellectricon offers a neuroscience discovery platform as its core offering, augmented by specialized testing services. The platform provides drug discovery and safety assessment services, with the Neurotoxicity Testing Services representing a new module that expands the platform's early safety assessment capabilities. The services utilize in vitro models with advanced assay technologies including optical electrophysiology, high-content imaging, and microfluidic systems to evaluate neurotoxicity endpoints.

Differentiator

Problem solved

Functional benefit

Products and services

  • Neurotoxicity Testing Services In vitro neurotoxicity testing services that leverage validated models with advanced assays including optical electrophysiology, high-content imaging, and microfluidic systems to evaluate acute and chronic neurotoxicity endpoints of drug candidates. Aimed at pharmaceutical and biotech developers, particularly those working on oligonucleotide-based therapeutics.
  • Neuroscience Discovery Platform Cellectricon's core platform providing neuroscience research and cell-based screening services for drug discovery, now expanded to include neurotoxicity testing capabilities for early safety assessment of drug candidates.

Companies that use Cellectricon

Customer profile

Segments1 record

Ideal customer profiles1 record

Cellectricon technology and API

Technology

Technology focussed Yes

API detail

Has API
No
API docs
API detail

Core technology

AI maturity

App detail

Feature3 records

Cellectricon partnerships and signals

Strategic signal

Recent moves5 records

Expansion highlights4 records

Cellectricon competitors and assessment

Company assessment

Direct peers

  • Reaction Biology Corporation: Preclinical services provider offering in vitro pharmacology, DMPK, and safety assays. Comparable as a contract research services firm serving pharma and biotech discovery and safety workflows.
  • Neuroservice: Specialized CRO focused on electrophysiology and in vitro neuroscience assays for drug discovery. Directly comparable as a niche electrophysiology services provider competing in the same neurotoxicology testing space.
  • Inotiv: Preclinical CRO providing toxicology, safety pharmacology, and research models. Comparable as a direct competitor in contract preclinical safety and neurotoxicity testing services.
  • Metrion Biosciences: Specialist ion channel and neuroscience CRO offering electrophysiology and in vitro safety assays. Closely comparable as a niche preclinical services provider with overlapping electrophysiology-based neurotoxicology capabilities.
  • Evotec (incl. Cyprotex): Provides preclinical in vitro ADME, toxicology, and safety pharmacology services through Cyprotex. Closely comparable as a specialized in vitro toxicology services provider supporting drug discovery safety assessment.

Broad incumbents

  • Charles River Laboratories: Global preclinical CRO offering extensive safety assessment, neurotoxicology, and in vitro services. Directly comparable as a scaled incumbent competing for the same outsourced neurotoxicity testing budgets.
  • Bio-Techne: Life sciences tools and services company offering reagents, assays, and contract services including neuroscience applications. Comparable as an established player providing both enabling tools and adjacent services to neuroscience drug discovery.
  • WuXi AppTec: Large global CRO/CDMO offering preclinical toxicology and safety assessment services. Comparable as a scaled alternative for pharmaceutical customers seeking outsourced neurotoxicology testing.
  • Eurofins Discovery: Part of Eurofins Scientific, offering drug discovery, in vitro pharmacology, and safety screening services. Comparable as a broad life-sciences services provider with overlapping in vitro neuroscience and toxicology capabilities.
  • Pharmaron: Global CRO offering in vitro and in vivo preclinical services including safety assessment. Comparable as a broad preclinical services competitor for outsourced neurotoxicology testing.

Market position

Strengths4 records

Weaknesses4 records

Competitive moat3 records

Key risks5 records

Key highlights5 records

Customer concentration

Cellectricon social profiles

Digital presence

Cellectricon financial estimates

Financial estimate

Revenue estimate

Valuation estimate

Cellectricon leadership team

Management profile

Number of profiles

Profiles2 records

Cellectricon funding detail

Funding detail

Funding overview

Funding rounds3 records

Investors2 records

Funding detail is available on the Subscription and Enterprise plan.Contact sales →

Cellectricon M&A and investment

M&A and investment

M&A

Investments

M&A and investment is available on the Subscription and Enterprise plan.Contact sales →

Frequently asked questions about Cellectricon

What does Cellectricon do?

Cellectricon provides advanced cell-based in vitro neurotoxicity testing services for pharmaceutical and biotech drug developers. Using validated human-relevant neural models combined with optical electrophysiology, high-content imaging, and microfluidic assay systems, the company evaluates acute and chronic neurotoxicity endpoints in drug candidates during preclinical development. The service is particularly positioned for developers of oligonucleotide-based therapeutics who require specialized early-stage safety assessment.

Is Cellectricon a public or private company?

Cellectricon is a private company. It is classified as venture growth investor backed and is currently operating.

When was Cellectricon founded?

Cellectricon was founded in 2001. It employs 11 to 50 people.

Where is Cellectricon based?

Cellectricon is headquartered in Mölndal, Sweden, in the Europe region.

How does Cellectricon make money?

One revenue line is on record: neurotoxicity Testing Services.

Who are Cellectricon's main competitors?

Direct peers on record are Reaction Biology Corporation, Neuroservice, Inotiv, Metrion Biosciences and Evotec (incl. Cyprotex). Broad incumbents are Charles River Laboratories, Bio-Techne, WuXi AppTec, Eurofins Discovery and Pharmaron.

Does Cellectricon have an API?

No public API is recorded for Cellectricon.

What industry is Cellectricon in?

Cellectricon's product category is Preclinical Contract Research Organization (CRO) Services. Its primary akta.pro industry code is HLAGAFAJ, In Vitro Toxicology (Cell-based/Organ-on-chip), with a secondary code of HLAIALAC, Preclinical Development (Pharmacology, PK/PD, ADME, Toxicology). Its NAICS code is 541714 and its SIC code is 8734.

Unlock the full company data

50 free credits on sign-up, no credit card required.

Contact sales
Live signals
NatureTools for discovery of novel targets and molecules involved in neuroplasticityCellectricon presented a webcast on in vitro models for studying neuroplasticity, addressing low throughput and assay variability. The models quantify structural and functional changes for drug discovery, with case studies on screening novel drugs and elucidating mechanisms.Technology NetworksCellectricon Broadens Discovery Capabilities With Launch of Neurotoxicity Testing ServicesCellectricon announced the launch of new Neurotoxicity Testing Services, expanding its neuroscience discovery platform to support early safety assessment of drug candidates. The services leverage validated in vitro models with advanced assays including optical electrophysiology, high-content imaging, and microfluidic systems to evaluate acute and chronic neurotoxicity endpoints. The company reports growing demand for early-stage neurotoxicity testing, particularly from developers of oligonucleotide-based drugs.PR NewswireDelix Therapeutics Partners With Cellectricon, Expressive Neuroscience and Expands Science Team To Accelerate Drug Discovery and TranslatabilityDelix Therapeutics announced strategic collaborations with Cellectricon and Expressive Neuroscience to accelerate its drug discovery pipeline for neuroplasticity-promoting therapeutics targeting psychiatric and neurological conditions. The partnerships will provide Delix access to novel assays and CNS assay services to evaluate its library of more than 1,400 psychoplastogen compounds, with the company having recently presented joint research at the Society for Neuroscience's 2022 conference. Delix is also expanding its science team, including the addition of Alison Mungenast as Senior Director of Neuroplasticity, and expects to begin Phase 1 clinical trials on its lead candidates in the first half of 2023.GlobeNewswireNanotechnology Research from Sweden Highlighted at BIO2003 in WashingtonA BIO2003 panel on nanotechnology will feature European scientists discussing nano-machines and nano-tools for single-molecule analysis. Swedish and Swiss researchers, including Cellectricon and Gnothis, are active in the field. The session is chaired by Magnus Malmqvist of Bioventia.GlobeNewswireGyros AB Licenses Patented Technology to Cellectricon ABGyros AB finalized a licensing agreement with Cellectricon AB for a patent on elastomeric microfluidic devices. The patent covers processes used in Cellectricon's Dynaflow platform, which is adopted by major pharma. Gyros also licensed the same patent to Fluidigm Corporation.